TrialMolecular medicine (Cambridge, Mass.)2015

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Michael Brines et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.